with AM1 of less than 12 hours' duration and LV dysfunction, were studied. LV dysfunction was defined by the presence of bibasilar pulmonary rales and/or third heart sound and LV filling pressure (LVFP) of more than 15 mm Hg. Four patients had ECG evidence of anterior and one of inferior transmural AMI. The diagnosis of transmural infarction was based on ECG findings of acute ST segment elevation followed by development of pathologic Q waves or substantial decrease in R wave voltage, coincident with serum myocardial enzyme changes typical of AMI. Three patients were in Killip class II and two patients were in Killip class IIL'O Conventional treatment, including sedation, oxygen, narcotics, and antiarrhythmic agents such as lidocaine, was prescribed when indicated but the administration of any vasodilators, diuretics, or other agents with known substantive hemodynamic effects was withheld until hemodynamic study of PGE, had been completed.
Hemodynamic
determinatlons.
The patients were admitted to the coronary care unit and informed consent was obtained. A 7F Lexington thermodilution catheter was positioned in the pulmonary artery (PA) via an antecubital vein cutdown and a short plastic catheter was inserted percutaneously into the radial artery. PA pressure and systemic arterial pressure (AP) were monitored simultaneously by use of Statham P231D and Bently 800 transducers, respectively. Cardiac output (CO) was measured by the thermodilution technique with the use of 10 ml of sterile normal saline at room temperature. Each CO recorded was the mean of at least two consecutive deter- The following indices were derived: SW1 = SVI X (MSP -LVFP) X 1.36/100, where SW1 represents stroke work index (gm . m/m2), SVI is stroke volume index (ml/m*), and MSP is mean systemic pressure (mm Hg). SVR = K (mean aortic pressure)/systemic flow = 80 @@/CO, and PVR = K (mean pulmonary pressure)/pulmonary flow = 80 (m)/CO, where SVR represents systemic vascular resistance, PVR is total pulmonary vascular resistance, m is mean aortic pressure, and i% is mean pulmonary pressure; K represents the conversion factor from hybrid unite of mm Hg . L-' . min-' to metric units of dyne . set . cmm5. PAR = (PA -LVFP x SO)/CO, where PAR is pulmonary arteriolar resistance. Table I . During PGE, infusion, HR increased slightly but did not reach statistical significance.
However, there were significant decreases in mean systemic arterial pressure (MAP) and mean pulmonary pressure (MPP) (Fig. 1 In one patient, the pulmonary capillary wedge pressure remained normal for up to 2 hours.
Anti-lschemic eftects.Three patients had complete relief of their chest pain during PGE, infusion. There were, however, no significant ST changes in the monitored precordial lead.
Side effects. No major side effects were encountered during the PGE, infusion; in particular there was no abdominal discomfort, vomiting or diarrhea. However, it should be pointed out that this was a pilot study with only a short duration of infusion. One patient had transient nausea but did not feel this sufficient to discontinue study.
DISCUSSION
Beneficial hemodynamk effects of POE, in AMI with congestive heart failure (CHF) due to balanced sy8temic arteriovenous dilation.
The present study demonstrates that administration of PGE, to patients with AM1 complicated by CHF results in significant hemodynamic improvement and relief of LV dysfunction without significant tachycardia or other side effects. The lack of substantive untoward extracardiac events such as nausea, vomiting, and diarrhea despite hemodynamic improvement may be related to the relatively small doses of PGE, necessary to reduce LVFP and SVR, thereby relieving pulmonary congestion and improving pump output. Although previous animal studies have not suggested an effect of PGE, on venous capacitance, the results of the present study demonstrate reduction of LVFP to normal with moderate decrease in SVR accompanied by only modest rises in SV and CI. Thus, the considerable reduction in LVFP suggests that in AM1 patients with CHF, PGE, therapy results in systemic venorelaxation.
Potential anti-ischemic properties of PGE,. Although the present study was designed to examine the acute hemodynamic actions of PGE1, this agent is also known to have other effects that may be of benefit in myocardial ischemia. PGE, has been shown to preserve myocardial cells during ischemia and diminish autolytic processes as evidenced by decreased myocardial creatine kinase (CK) and cathepsin D release and by preservation of myocardial CK activity, indicating protection of cardiac cell integrity.7**1 PGE, increases coronary blood flow and decreases coronary vascular resistance.', l2 PGE, also protects against isoproterenol-induced myocardial injury as evidenced by significant reductions in ST segment elevation and plasma free fatty acid concentration. 13 In addition, PGEI, inhibits norepinephrine releaseI and the attendant increase in lipolysis, thereby limiting the deleterious myocardial oxygen wasting effect resulting from catecholamine rise during AMI. The coronary vasodilatory action of PGE, in con- junction with reduced LV preload might favorably redistribute myocardial perfusion toward the subendocardium, the area most critically compromised during acute ischemia. It is also possible that PGE, might increase collateral blood flow directly or by reducing LVFP. Of particular interest is PGE, inhibition of platelet aggregation,15 since recent studies have indicated increased platelet aggregation in AM1 patients and a pathogenetic role of such platelet dysfunction in the infarction process.'"-'* Potential advantages of PGE, compared to other vasodllators in AM. The beneficial hemodynamic effects observed in the present study have also been observed with other vasodilators such as nitroprusside and nitroglycerin. ls, 2o However, the use of nitroprusside in the presence of acute myocardial ischemia has been of concern to some workers, since animal studies have suggested that nitroprusside may adversely alter the distribution of myocardial blood flow during experimental infarction.21s22 Hence, an alternative means of acute afterload reduction appears useful. While not directly compared, the effects of PGE, in this study seem similar to the balanced systemic arterial and venous dilation caused by nitroprusside, as shown by the 16% increase in SV and 29% reduction in LVFP produced by PGE,. Nitroglycerin exerts a beneficial hemodynamic effect in AM1 patients without increasing ST segment elevation or adversely affecting distribution of myocardial perfusion.20 However, nitroglycerin does not possess some of the other potential salutary properties of PGE, such as inhibition of catecholamine release and diminished platelet aggregation. While another prostagl&ndin, prostacyclin (PGI,), provides greater in vitro anti&&&t aggregation and more potent coronary vasodilation April. 1982 
American
Heart Journal compared to PGE,, the use of PGI, in AM1 patients with congestive heart failure appears limited due to marked PGI,-induced systemic vasodilation and hypotension.
Conclusions.
Although the number of patients included in the present study was relatively small, the salutary hemodynamic results are significant. In view of our clinical observations and the experimental data of others suggesting additional beneficial actions of PGE1, this therapeutic agent deserves further evaluation in the management of patients with AM1 and LV failure. able controversy concerning the short-and longterm salutary effects of digitalis on left ventricular (LV) performance in the normal and the failing heart. While most experimental animal and patient studies have demonstrated an enhancement of LV performance by digitalis?-" other studies have demonstrated minor or variable improvement.18-22 The effects of the cardiac glycosides on LV performance may vary depending on the pretreatment inotropic state, the peripheral vascular resistance, the route of administration, the level of circulating
